Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Genomics of Acute Myeloid Leukemia at Diagnosis and Remission.
Journal: medRxiv : the preprint server for health sciences
Published: December 17, 2025
Novel antibodies for identification, selection, and manipulation of T cells expressing Whitlow linker-containing CARs.
Journal: Journal for immunotherapy of cancer
Published: October 28, 2025
Donor-derived del[20q] following allogeneic-hematopoietic cell transplantation: a case with 26-year follow-up and literature review.
Journal: Bone marrow transplantation
Published: July 22, 2025
Graphical and Interactive Spatial Proteomics Image Analysis Workflow.
Journal: bioRxiv : the preprint server for biology
Published: June 12, 2025
Spatial proteomics and transcriptomics characterization of tissue and multiple cancer types including decalcified marrow.
Journal: Cancer biomarkers : section A of Disease markers
Published: March 20, 2025
Analytical Performance of the NCI-myeloMATCH Assay: A Rapid Turnaround Genomic Profiling Assay for Myeloid Disorders.
Journal: The Journal of molecular diagnostics : JMD
Published: January 28, 2025
A clinical solution for tracking clonal evolution of acute myeloid leukemia after allogeneic transplantation using bulk next generation sequencing.
Journal: Bone marrow transplantation
Published: December 04, 2024
Erratum to: Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies.
Journal: Haematologica
Published: July 01, 2024
Evaluation of Acute Myeloid Leukemia Genomes using Genomic Proximity Mapping.
Journal: medRxiv : the preprint server for health sciences
Published: June 10, 2024
Leukemic non-nodal cyclin D1- and SOX11-negative mantle cell lymphoma with CCND3::IGH rearrangement.
Leukemic non-nodal cyclin D1- and SOX11-negative mantle cell lymphoma with CCND3::IGH rearrangement.
Journal: Annals of hematology
Published: August 14, 2023
Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma.
Journal: Cancer research communications
Published: February 23, 2022
Last Updated: 09/26/2026